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Specific expression of the Epstein-Barr virus (EBV) immediate-early and early gene products Zta, Rta, I'ta,
and MSta by a recombinant vaccinia virus system allowed us to analyze the first steps in the induction of the
lytic cycle in EBV-infected Burkitt lymphoma (BL) cells and lymphoblastoid cell lines (LCLs). Significant
differences in the induction of early genes were found between these cell types: whereas in BL cells the trans
activator Zta was found to induce key steps of the early lytic cycle, only minor activities of Zta were noted in
LCLs. Contrary to Zta, the trans activator Rta was found to be highly effective in LCLs. These observations
suggest that Rta may play an important role in the activation of the early lytic cycle in LCLs, although it cannot
be activated by Zta. The latter may be a reason for the lower tendency of LCLs to switch into the lytic cycle
compared with BL cells or differentiated epithelial cells.
Epstein-Barr virus (EBV) infects human B lymphocytes and
certain epithelial cells. Infection of B lymphocytes is predom-
inantly latent; the virus persists lifelong in a small number of
these cells which are regarded as the reservoir of the virus. In
epithelial cells, on the other hand, the lytic cycle is frequently
induced, leading to the production of progeny virus (1, 31).
Viral latency in B lymphocytes can be disrupted in vitro by
chemical agents such as 12-O-tetradecanoylphorbol-13-acetate
(TPA) (36) and by cross-linking of immunoglobulin (29) on the
surface of latently infected cells. The switch from latency to
lysis is associated with the expression of the immediate-early
trans activators Zta (also termed Z, ZEBRA, or EB1), en-
coded by the open reading frame BZLF1, Rta (or R), encoded
by BRLF1, and I'ta, derived from BI'LF4 (2, 22). Zta is a
member of the AP-1 family of transcription activators (4, 7);
Rta was shown to be an enhancer-binding factor (14). Zta and
Rta induce the expression of proteins of the early group such
as the MSta protein (also termed MS-EA or EB2), encoded by
the open reading frame BSLF2/BMLF1, and the p138 derived
from BALF2 (3, 5, 14, 34). These early events lead to a cascade
of expression of about 80 viral genes, viral DNA replication,
and finally the release of progeny virions and cell death (13).
Induction of the lytic cycle followed by virus production
seems to be a rare event in B lymphocytes in vivo. This may be
due to immunological surveillance mechanisms by which cells
entering the lytic cycle are killed before progeny viruses are
produced; however, disruption of latency in these cells may
also be impeded by cell-specific genetic mechanisms.
Most of our knowledge about the early events during the
lytic cycle stems from experiments with Burkitt lymphoma
(BL) cells. However, it is doubtful whether these malignant
cells are comparable to the normal resting B cells harboring
the virus in healthy individuals. The initial events in the
induction of the lytic cycle may differ in the latter, as a different
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cellular environment may well influence the activation of viral
genes. Recently, differences in early activation steps between
epithelial cells and BL cells were demonstrated (33).
In this investigation, we therefore compared the key steps in
the induction of the lytic cycle in BL cells and EBV-positive
lymphoblastoid B-cell lines (LCLs), which because of their
nonmalignant state may resemble the normal EBV-infected B
lymphocytes more closely. We concentrated our analysis on the
very early events characterized by the expression of the Zta,
Rta, and I'ta proteins. Recombinant vaccinia viruses contain-
ing the genes coding for Zta, Rta, I'ta, and MSta were used to
express these proteins in different BL and lymphoblastoid cell
lines and to study the influence of each of these proteins on the
expression of the other immediate-early trans activators and
the early proteins MSta and p138 encoded by BALF2. The
feasibility of such an approach for gene regulation studies was
recently demonstrated by Zhu et al. working with immediate-
early trans activators of herpes simplex virus (35). Our study
showed considerable differences in the early induction path-
ways between LCLs and BL cells.
Expression of Zta, Rta, I'ta, and MSta. We inserted the
coding sequences of the EBV trans activators Zta, Rta, I'ta,
and MSta in vaccinia viruses under the control of the early/late
7.5K promoter, using the protocol of Mackett and coworkers
(18). Coding regions of the reading frames BZLF1, BRLF1,
BI'LF4, and BSLF2/BMLF1 were cloned in the correct orien-
tation in the plasmid construct pAvB (30) adjacent to the 7.5K
promoter, flanked on either side by vaccinia virus thymidine
kinase (TK) sequences. CV1 cells infected with wild-type
vaccinia strain WR were transfected with the plasmid construct
by the CaPO4 method (10). Homogeneous recombination gave
rise to TK-negative recombinants, which were selected by
5-bromodeoxyuridine in TK-negative B143 cells (19). Cells
infected with these recombinant viruses were assayed for
foreign gene expression by Western blotting (immunoblotting).
Virus was cloned twice prior to large-scale preparations of
virus stocks by serial passaging on CV1 cells. The recombinant
vaccinia virus strains expressing Zta, Rta, I'ta, and MSta were
called Z-Vac, R-Vac, I'-Vac, and M-Vac, respectively. Infec-
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FIG. 1. Western blots demonstrating expression of the EBV trans
activator proteins Zta, Rta, I'ta, and MSta by infection of CV1 cells
with Z-Vac (A), R-Vac (B), I'-Vac (C), and M-Vac (D). Vaccinia virus
wild-type strain WR-infected CV1 cells served as a negative control
(VWR). Zta has a size of 35 kDa (A), Rta expression results in a band
of 94 kDa (B), and I'ta is a protein of 48 kDa (C). MSta expression
results in a pattern of different posttranslationally modified forms with
molecular sizes of between 42 and 66 kDa (D), as described by Wong
and Levine (32). Polyclonal rabbit antisera directed against Zta, Rta,
I'ta, and MSta are described elsewhere (21, 22).
tion of various cell lines with the recombinant vaccinia viruses
resulted in an efficient expression of the different trans activa-
tor proteins (Fig. 1).
LCLs obtained by immortalization of B lymphocytes with
EBV strain B 95-8 and EBV-positive BL cell lines Akata (29),
Eli (27), Jijoye (12), Daudi (16), P3HR-1 (12), and Raji (25)
were infected with one of these recombinants at a time (2 x
106 cells at a multiplicity of infection of 5 in a 100-,ul volume).
Virus adsorption was allowed for 1 h at 37°C, and then 2 ml of
RPMI 1640 containing 10% fetal calf serum was added. EBV
gene expression was analyzed after 2 days of incubation at 37°C
in 10% CO2. The infected cells were analyzed for the expres-
sion of the immediate-early proteins Zta, Rta, and I'ta and of
the early gene products p138 and MSta by Western blotting.
Cells were solubilized, and an equivalent of 6 x 105 cells was
loaded into one lane of a 15 or 17% sodium dodecyl sulfate-
polyacrylamide gel (17). Western blotting was performed as
described elsewhere (21). No significant differences in the level
of expression between LCLs and BL cells were found in
parallel experiments.
Gene expression in BL cells. As expected, in BL cell lines,
B
FIG. 3. Expression of MSta in BL lines and LCLs. BL lines Jijoye
(A) and Eli (B) and LCLs derived from two donors (C and D) were
infected with the recombinant vaccinia virus constructs Z-Vac, R-Vac,
I'-Vac, and M-Vac and with vaccinia virus wild-type strain WR
(VWR). Blots were stained with an MSta-specific polyclonal rabbit
antiserum (21).
the Zta protein showed a dominating influence on the expres-
sion of other transactivators and of p138. In all BL lines
studied, infection with the recombinant vaccinia virus Z-Vac
led to high expression of the trans activators Rta (Fig. 2A and
B) and MSta (Fig. 3A and B) and significantly increased the
expression of p138 (Fig. 4A and B) in four cell lines from low
basal expression. No clear effect on p138 was observed in the
cell line P3HR-1, which constitutively expresses this protein at
a high level, and in the Raji line, which has a deletion of the
BALF2 gene coding for p138 (data not shown). In none of the
BL lines could induction of the I'ta protein by Zta be seen.
Infection of BL cells with R-Vac, M-Vac, or I'-Vac showed
only minor or no influence on the expression of other EBV
proteins. Low amounts of MSta protein were expressed in
P3HR-1 cells infected with R-Vac (not shown); no other effects
of Rta, MSta, and I'ta on the different trans activators or p138
were observed in the six BL lines studied (Fig. 2A and B, 3A
and B, and 4A and B).
Gene expression in LCLs. A clearly distinct induction pat-
tern was seen when EBV-transformed LCLs were infected with
the recombinant vaccinia virus constructs. In these cells, the
influence of Zta was considerably lower. Only the MSta
protein was weakly expressed in two of five LCLs infected with
Z-Vac (Fig. 3D), whereas none of the other transactivators nor
p138 could be detected in these cells. On the other hand, Rta,
which had only a marginal effect on the expression of EBV
proteins in BL cells (see above), led to the expression of MSta
in four of five LCLs and of p138 in three of five LCLs (Fig. 2C
and D, 3C and D, and 4C and D). No clear effect on p138
expression was demonstrable in two lines, as these cells already
expressed this protein at a high level (data not shown). The
transactivators I'ta and MSta behaved similarly as in BL cells:11t40
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FIG. 2. Expression of Rta in BL lines and LCLs. BL lines Jijoye (A)
and Eli (B) and LCLs derived from two donors (C and D) were
infected with the recombinant vaccinia virus constructs Z-Vac, R-Vac,
I'-Vac, and M-Vac and with vaccinia virus wild-type strain WR
(VWR). Blots were stained with an Rta-specific polyclonal rabbit
antiserum (21).
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FIG. 4. Expression of p138 in BL lines and LCLs. BL lines Jijoye
(A) and Eli (B) and LCLs derived from two donors (C and D) were
infected with the recombinant vaccinia virus constructs Z-Vac, R-Vac,
I'-Vac, and M-Vac and with vaccinia virus wild-type strain WR
(VWR). Blots were stained with a monoclonal antibody reactive
against p138 (24).
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TABLE 1. EBV early lytic cycle activation steps observed following infection with recombinant vaccinia viruses
Recombinant vaccinia No. of BL cell lines' expressing: No. of LCLs expressing:
virus used for Zta Rta I'ta MSta p138 Zta Rta I'ta MSta p138
infection (n 6) (n = 6) (n = 6) (n = 6) (n =4) (n = 5) (n = 5) (n = 5) (n = 5) (n = 3)
Z-Vac 6 0 6 4 0 0 2 0
R-Vac 0 0 1 0 0 0 4 3
I'-Vac 0 0 0 0 0 0 1 0
M-Vac 0 0 0 0 0 0 0 0
a Number of cell lines in which the respective protein was induced by the indicated recombinant vaccinia virus.
no activation of any other EBV protein was observed in LCLs
infected with M-Vac, whereas in one of five LCLs infected with
I'-Vac, induction of MSta protein was found (Fig. 3C). Table
1 summarizes the results obtained in BL lines and LCLs.
The immediate-early gene products Zta, Rta, and I'ta are
known to induce the expression of early gene products such as
MSta and p138 (3, 5, 14, 22, 34). Zta can be transcribed from
two promoters (20, 28) which induce two different transcripts:
they contain either the reading frame BZLF1 alone or the two
reading frames BZLF1 and BRLF1 as a bicistronic message,
the latter giving rise to the expression of Zta and Rta. Zta has
been shown to stimulate transcription from either of the two
promoters (8, 28), thus inducing the expression of Rta as well
as enhancing its own expression. The activation of the produc-
tive cycle by transfection of Zta (26) demonstrated the key role
of this protein for the replication of EBV. So far, Zta has been
found to be the only trans activator able to induce the lytic
cycle when acting alone (6, 11, 26). However, this mechanism,
demonstrated so far mostly in BL cells, does not seem to work
in LCLs, as shown clearly by our results. This observation
agrees well with earlier observations that LCLs seem to be less
permissive for lytic infection than BL cells (9, 23). In LCLs,
Rta may play an important role in lytic activation, as docu-
mented by the activation of the early genes BSLF2/BMLF1
coding for MSta and BALF2. Rta seems to act alone in this
case. Zta alone is obviously not able to induce the full lytic
cycle, possibly because of its failure to activate Rta expression.
The induction of Zta by Rta is theoretically possible by
activation of the transcription unit for the 2.8-kb RNA which
contains the message for Rta and Zta (28). This, however, does
not seem to play a role under these conditions, as in no case
could the expression of Zta be detected after infection with the
vaccinia virus construct leading to Rta expression. On the
other hand, in BL cells, the induction of Zta always led to Rta
expression; probably the presence of Zta and Rta together
mediates the induction of MSta and p138 in BL cells. However,
the expression of Rta alone had no effect on the induction of
the later proteins.
These experiments demonstrate that cellular factors play an
important role in the very early events during the replication
pathway of EBV. Indeed, several cellular factors influencing
the early lytic cycle of EBV have recently been described (15,
33). Such factors may act differently in nonmalignant LCLs and
malignant BL cells; these cells may differ, for example, in the
repertoire of transcription factors involved in enhancement or
in inhibition of the trans-activating effects of Zta or Rta. It may
well be that in the small resting B lymphocytes which harbor
EBV in the healthy host, factors similar to those in nonmalig-
nant LCLs are active (or missing). This would explain why
productive infection in these cells, which could lead to viremia
and potential endogenous reinfection, seems to be a rare
event. The low inducibility of the lytic cycle in these cells may
be due to the long coevolution of virus and host, as the result
of a selective pressure in the normal lymphocyte to avoid viral
replication and cell death.
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